Sarepta Therapeutics Inc (SRPT)
Cash ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Cash and cash equivalents | US$ in thousands | 1,103,010 | 428,430 | 966,777 | 2,115,870 | 1,502,650 |
| Short-term investments | US$ in thousands | 251,782 | 1,247,820 | 1,022,600 | 0 | 435,923 |
| Total current liabilities | US$ in thousands | 731,684 | 653,659 | 619,604 | 452,733 | 416,026 |
| Cash ratio | 1.85 | 2.56 | 3.21 | 4.67 | 4.66 |
December 31, 2024 calculation
Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($1,103,010K
+ $251,782K)
÷ $731,684K
= 1.85
The cash ratio of Sarepta Therapeutics Inc has fluctuated over the years based on the provided data. In December 31, 2020 and 2021, the company had a healthy cash ratio of 4.66 and 4.67, indicating that they had $4.66 and $4.67 in cash and cash equivalents for every dollar of current liabilities, respectively.
However, in the following years, the cash ratio decreased significantly. By December 31, 2022, the ratio dropped to 3.21, indicating a lower level of liquidity compared to the previous years. This downward trend continued in December 31, 2023, with a cash ratio of 2.56, and by December 31, 2024, it further decreased to 1.85.
The decreasing cash ratio over the years suggests that Sarepta Therapeutics Inc may be experiencing challenges in maintaining sufficient liquid assets to cover its short-term obligations. This trend indicates the need for the company to closely monitor and manage its liquidity position to ensure its ability to meet its financial obligations in a timely manner.
Peer comparison
Dec 31, 2024